Literature DB >> 12969265

Attenuated 5-HT1A receptor signaling in brains of suicide victims: involvement of adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-activated protein kinase.

Shu-chi Hsiung1, Mella Adlersberg, Victoria Arango, J John Mann, Hadassah Tamir, Kuo-peing Liu.   

Abstract

Positron emission tomography studies in major depression show reduced serotonin (5-HT)1A receptor antagonist-binding potentials in many brain regions including occipital cortex. The functional meaning of this observation in terms of signal transduction is unknown. We used postmortem brain samples from depressed suicide victims to examine the downstream effectors of 5-HT1A receptor activation. The diagnosis was established by means of psychological autopsy using Diagnostic and Statistical Manual of Mental Disorders (DSM) III-R criteria. Measurements of [35S]GTPgammaS binding to Galphai/o in the occipital cortex of suicide victims and matched controls revealed a blunted response in suicide subjects and a decrease in the coupling of 5-HT1A receptor to adenylyl cyclase. No significant group differences were detected in the expression levels of Galphai/o, Galphaq/11 or Galphas proteins, or in the activity of cAMP-dependent protein kinase A. Studies of a parallel transduction pathway downstream from 5-HT1A receptor activation demonstrated a decrease in the activity of phosphatidylinositol 3-kinase and its downstream effector Akt, as well as an increase in PTEN (phosphatase and tensin homolog deleted on chromosome 10), the phosphatase that hydrolyzes phosphatidylinositol 3,4,5-triphosphate. Finally, the activation of extracellular signal-regulated kinases 1 and 2 was attenuated in suicide victims. These data suggest that the alterations in agonist-stimulated 5-HT1A receptor activation in depressed suicide victims are also manifest downstream from the associated G protein, affecting the activity of second messengers in two 5-HT1A receptor transduction pathways that may have implications for cell survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969265     DOI: 10.1046/j.1471-4159.2003.01987.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  57 in total

1.  The viral theory of schizophrenia revisited: abnormal placental gene expression and structural changes with lack of evidence for H1N1 viral presence in placentae of infected mice or brains of exposed offspring.

Authors:  S Hossein Fatemi; Timothy D Folsom; Robert J Rooney; Susumu Mori; Tess E Kornfield; Teri J Reutiman; Rachel E Kneeland; Stephanie B Liesch; Kegang Hua; John Hsu; Divyen H Patel
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

2.  Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Authors:  Sabrina D Robertson; Heinrich J G Matthies; W Anthony Owens; Vidiya Sathananthan; Nicole S Bibus Christianson; J Phillip Kennedy; Craig W Lindsley; Lynette C Daws; Aurelio Galli
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 3.  GSK3beta: role in therapeutic landscape and development of modulators.

Authors:  S Phukan; V S Babu; A Kannoji; R Hariharan; V N Balaji
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 4.  The serotonin1A receptor: a representative member of the serotonin receptor family.

Authors:  Thomas J Pucadyil; Shanti Kalipatnapu; Amitabha Chattopadhyay
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

5.  The PTEN phosphatase is essential for long-term depression of hippocampal synapses.

Authors:  Yue Wang; Aiwu Cheng; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

6.  Regulation of glycogen synthase kinase-3 in patients with affective disorders.

Authors:  W Timothy O'Brien; Peter S Klein
Journal:  Biol Psychiatry       Date:  2007-01-15       Impact factor: 13.382

Review 7.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

8.  FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder.

Authors:  Katarzyna A Ellsworth; Irene Moon; Bruce W Eckloff; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Joanna M Biernacka; Ryan Abo; Abra Brisbin; Yuan Ji; Scott Hebbring; Eric D Wieben; David A Mrazek; Richard M Weinshilboum; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2013-03       Impact factor: 2.089

9.  GSK-3β inhibition protects mesothelial cells during experimental peritoneal dialysis through upregulation of the heat shock response.

Authors:  K Rusai; R Herzog; L Kuster; K Kratochwill; C Aufricht
Journal:  Cell Stress Chaperones       Date:  2013-03-14       Impact factor: 3.667

10.  Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder.

Authors:  Bernadeta Szewczyk; Paul R Albert; Ariel M Burns; Margaret Czesak; James C Overholser; George J Jurjus; Herbert Y Meltzer; Lisa C Konick; Lesa Dieter; Nicole Herbst; Warren May; Grazyna Rajkowska; Craig A Stockmeier; Mark C Austin
Journal:  Int J Neuropsychopharmacol       Date:  2008-06-19       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.